98%
921
2 minutes
20
Poloxamer 188 (P188) possesses anti-inflammatory properties and can help to maintain plasma membrane function. P188 has been reported to exert beneficial effects in the treatment of various disorders. However, the effects of P188 in ischemia/reperfusion (IR)-induced acute lung injury have not been examined. We investigated the ability of P188 to attenuate IR-induced acute lung injury in rats and hypoxia/reoxygenation (HR) injury in murine epithelial cells. Isolated perfused rat lungs were exposed to 40 min ischemia followed by 60 min reperfusion to induce IR injury. IR led to lung edema, increased pulmonary arterial pressure, promoted lung tissue inflammation and oxidative stress, and upregulated the levels of TNF-α, IL-6 and CINC-1, and increased Lactic dehydrogenase (LDH) activity in bronchoalveolar lavage fluid. IR also downregulated the levels of inhibitor of κB (IκB-α), upregulated nuclear factor (NF)-κB (NF-κB), and promoted apoptosis in lung tissues. P188 significantly suppressed all these effects. P188 also exerted a similar effect in murine lung epithelial cells exposed to HR. Furthermore, P188 reduced the number of propidium iodide-positive cells, maintained cell membrane integrity, and enhanced cell membrane repair following HR. We conclude that P188 protects against lung IR injury by suppressing multiple signaling pathways and maintaining cell membrane integrity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319770 | PMC |
http://dx.doi.org/10.3389/fphar.2021.650573 | DOI Listing |
Eur Heart J
September 2025
Cardiovascular and Genomics Research Institute, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Myocardial infarction (MI) is defined pathologically as myocardial cell death resulting from prolonged ischaemia. The clinical definition of this pathological process relies on clinical evidence of myocardial ischaemia and biomarker evidence of myocardial cell death. Cardiac troponins are the standard clinical biomarker for assessing cardiac cell death.
View Article and Find Full Text PDFPediatr Pulmonol
September 2025
Department of Neonatology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India.
Background: Meconium aspiration syndrome (MAS), a common cause of respiratory failure in late preterm and term neonates, is associated with a high risk of mortality and morbidity. Amongst all the treatment modalities for severe MAS, surfactant administration has a proven role in decreasing progressive respiratory failure.
Methods: The present open-label randomised controlled trial aimed to determine the effect of early (≤ 2 h) bolus surfactant therapy as compared to standard care on the total duration of respiratory support.
Pediatr Pulmonol
September 2025
Division of Pulmonary Medicine, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Objective: Bronchopulmonary dysplasia (BPD) is the most common cause of chronic lung disease in infancy. Caregivers often experience significant challenges in caring for these medically complex children. The purpose of this study was to determine feasibility of administering an electronic social determinants of health (SDoH) screening tool and to determine if caregiver social needs correlate with respiratory outcomes in children with BPD.
View Article and Find Full Text PDFGen Physiol Biophys
September 2025
Pneumology Department, Zigong First People's Hospital, Zigong, China.
Chronic obstructive pulmonary disease (COPD) is characterized by airway remodeling and inflammation. Cigarette smoke extract (CSE) induces apoptosis, inflammation, and oxidative stress in COPD. Tripterygium glycosides (TG) are an active compound found in the root extracts of Tripterygium wilfordii Hook F (TWHF) that possesses anti-inflammatory and immunosuppressive effects.
View Article and Find Full Text PDFPediatr Pulmonol
September 2025
Perinatal Institute, Division of Neonatology and Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Objective: To wean respiratory support, preterm infants with severe respiratory failure are often administered systemic corticosteroids. We sought to evaluate if postnatal age or clinical characteristics predicted death or tracheostomy following systemic dexamethasone in evolving bronchopulmonary dysplasia.
Study Design: We performed a retrospective study of infants born at ≤ 30 weeks' gestational age cared for at a Level IV referral center from 2009 to 2019 who received a complete course of systemic dexamethasone beyond 4 weeks of age for the indication of preventing death and/or liberating from positive pressure ventilation.